Sumitomo Mitsui Trust Group’s PTC Therapeutics PTCT Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$262K	Buy	+3,208	New	+$232K	﹤0.01%	1044

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Sumitomo Mitsui Trust Group's PTCT Position: Q2 2026 in Review

Sumitomo Mitsui Trust Group opened a new position in PTC Therapeutics (PTCT) in Q2 2026: 3,208 shares worth $262K. The stake represents ﹤0.01% of the portfolio and ranks #1044 among its holdings.

382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

Sumitomo Mitsui Trust Group held 3,208 shares of PTC Therapeutics worth $262K as of Q2 2026.
PTC Therapeutics was a new Sumitomo Mitsui Trust Group position in Q2 2026.
PTC Therapeutics made up ﹤0.01% of Sumitomo Mitsui Trust Group's portfolio in Q2 2026, its #1044 holding.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q2 2026, filed 30 Jul 2026.